The global antacids market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033. The market is experiencing growth mainly because of the expansion of retail pharmacies, preference for OTC drugs, and rising number of patients experiencing gastroesophageal reflux disease (GERD) are impelling the growth of the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 7.2 Billion |
Market Forecast in 2033
|
USD 9.7 Billion |
Market Growth Rate (2025-2033) | 3.4% |
Gastroesophageal reflux disease’s (GERD) impact
783.95 million people were impacted by GERD in 2019 claimed by the report of the National Library of Medicine 2022. The more people going through the suffering of GERD, the more it is driving the demand for antacids. The best treatment for acidity is thought to be antacids because of their several qualities. Individuals are aware about the quick relief provided by antacids and their easy accessibility is further contributing to the antacids market growth.
Changing demographics because of rising geriatric population
Elderly people are understanding the importance of antacids because of their quick relief qualities from acidity. They are, as a result, a regular consumer or buyer of antacids to manage these digestive issues. It may be said that nations with increased aging population rates can have higher sales of antacids worldwide. As claimed by the World Health Organization’s (WHO) report of 2022, 1 individual out of 6 will be of 60 years in age or over by 2030 and by 2050. The global population of those aged 60 and over will also reach 2.1 billion, up from 1.4 billion in 2020.
Rising reliance on over the counter (OTC) medicines due to their ease of availability
Non-prescribed remedies are highly preferred in the world to cure mild symptoms, which is catalyzing the antacids demand. Antacids are easily available via pharmacies, grocery stores, and online platforms and as a result play a crucial role in self-medication purposes. The cost-effectiveness and time saving benefits provided by antacids are making them highly suitable for people nowadays. The IMARC Group’s research report mentions that the global market for over the counter (OTC) drugs will reach US$ 275.9 Billion by 2032.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on drug class, formulation type, and distribution channel.
Breakup by Drug Class:
Proton pump inhibitors accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes proton pump inhibitors, H2 antagonist, acid neutralizers, & pro-motility agents. According to the report, proton pump inhibitors represent the largest segment.
Proton pump inhibitors are so effective and reliable that everyone wants them to cut down on stomach acid and indigestion. Healthcare professionals prescribed them as per the severity of acid reflux, leading to their higher sales. Key players are expanding their market as they know people are gaining knowledge about the positive impact of proton pump inhibitors in the body. For instance, Daewon Pharmaceutical introduced its first proton pump inhibitor medicine in Korea in 2022, known as Escorten.
Breakup by Formulation Type:
Tablet holds the largest share of the industry
A detailed breakup and analysis of the market based on the formulation type have also been provided in the report. This includes tablet, liquid, powder, and others. According to the report, tablet accounts for the majority of the market share.
Easy storage, transportation, and administration are some benefits provided by tablets make them highly preferable among individuals. Tablets are hassle-free, as they can be easily consumed with water anywhere or on the go. Whether at office, home, or travel, people can get quick relief from acidity or indigestion through tablet drugs. The extended shelf life of tablets is viewed as another benefit compared to liquid or powder formulation type. Various tablets formulations present in the antacids market like chewable, delayed release, and effervescent are further creating a strong consumer base.
Breakup by Distribution Channel:
Retail pharmacies represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and others. According to the report, retail pharmacies dominate the market.
In the first place, cities, suburbs, and rural areas all have numerous retail pharmacies around the world. Antacids as OTC drugs are highly popular & retail pharmacies are a significant outlet to purchase antacids. Secondly, the inclusion of a wide variety of antacids drugs in retail pharmacies can cater to several patients according to their preferences and demands. Thirdly, the focus of leading competitors in the retail pharmacy market on acquisition & expansion to increase their reach. The acquisition of Pharmaca by Medly Pharmacy in 2021 to deliver 360-degrees pharmacy services is one such example.
Breakup by Region:
Asia Pacific leads the market, accounting for the largest antacids market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific enjoys the leading position in the market.
The densely populated countries like India and China are the largest markets for antacids in this region, as these countries are undergoing lifestyle shifts and Western food habits, which generally results in acid reflux and indigestion. Moreover, aging population in the region is viewed as an antacids market recent opportunities due to their high susceptibility to digestive issues. In line with this, lots of key players are present in the Asia Pacific region that are highly competitive and focus on partnerships and acquisition to expand their market. This was done by Dr. Reddy’s Laboratories, a pharma company in India, when it acquired MenoLabs from Amyris Inc. in 2024 to cater to the evolving needs of people in the Asia Pacific region.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major antacids companies have also been provided. Some of the major market players in the antacids industry include:
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
The development of new formulations and product variants is done by key players through research and development (R&D) activities. They are introducing antacid drugs with flavors such as Fruity Cereal to meet the evolving demands of consumers. Top companies are taking advantage of elevated awareness about gastrointestinal health among people in developing countries. They are also eyeing on acquiring small businesses in the market while creating opportunities via antacids market recent developments. Using the digital health solutions is the main help method, enabling them to provide better health results. One such example was presented by AstraZeneca in November 2023, which it launched Evinova, a health-tech business, to offer advanced digital health solutions.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Antacids Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Drug Classes Covered | Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents |
Formulation Types Covered | Tablet, Liquid, Powder, Others |
Distribution Channels Covered | Hospital Pharmacies, Retail Pharmacies, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global antacids market was valued at USD 7.2 Billion in 2024.
We expect the global antacids market to exhibit a CAGR of 3.4% during 2025-2033.
The rising demand for antacids in relieving inflammation, swelling, pain, and irritation associated with heartburn, along with the introduction of raft-forming antacids that are safe and have strong medications, which provide higher efficacy and increased duration of action, is primarily driving the global antacids market.
The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for antacids.
Based on the drug class, the global antacids market can be categorized into proton pump inhibitors, H2 antagonist, acid neutralizers, and pro-motility agents. Currently, proton pump inhibitors hold the majority of the total market share.
Based on the formulation type, the global antacids market has been segmented into tablet, liquid, powder, and others. Among these, tablet currently exhibits a clear dominance in the market.
Based on the distribution channel, the global antacids market can be bifurcated into hospital pharmacies, retail pharmacies, and others. Currently, retail pharmacies account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.
Some of the major players in the global antacids market include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.